GlassScriptPhysician profile
Peter N Davison
NPI 1013443654
$562.26
in general payments reported to CMS, 2019-2025
10 companies · $194 in 2025
The $194 reported for 2025 was more than what 75% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.38 · 2023: $161 · 2024: $192 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $547.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $174.13 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $62.52 | 2023 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $57.11 | 2024 | Lokelma |
| Novartis Pharmaceuticals Corporation | $52.74 | 2023-2024 | |
| Pfizer INC. | $48.38 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.31 | 2023-2024 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $40.77 | 2023 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $34.48 | 2019-2024 | Verquvo |
| Boston Scientific Corporation | $21.95 | 2025 | Watchman Flx |
| Janssen Pharmaceuticals, INC | $21.87 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Davison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.